Miguel Regueiro

In the last five years, there have been three distinct small molecules that have been approved for the management of ulcerative colitis…

BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…

BACKGROUND: Cancer is a major cause of morbidity and mortality in persons with inflammatory bowel disease (IBD). We evaluated temporal trends and relative risks of intestinal and extra-intestinal cancers among persons with IBD and matched controls…

INTRODUCTION: The ultimate goal of colorectal cancer (CRC) screening is to prevent CRC by detecting advanced adenomas that potentially progress to CRC…

An incisional hernia (IH) is one of the most frequent complications after a laparotomy, affecting between 10 -20% of patients…

Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…

Oral small molecules (OSM) have demonstrated effectiveness in treating IBD. Certain studies have associated certain OSM with an increased cancer risk. We aimed to assess the cancer risk in IBD patients treated with OSM…

SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented…

INTRODUCTION: Recent guidelines propose a fecal calprotectin (FCP) monitoring strategy in the year after Crohn’s disease (CD) resection for low-risk individuals or those receiving pharmacologic prophylaxis to prevent postoperative recurrence (POR)…

The evaluation of volatile organic compounds (VOCs) in exhaled breath shows promise as an entirely non-invasive strategy to evaluate for inflammation with high patient acceptance…